Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acid suppression therapy: where do we go from here?

Carmelo Scarpignato1, Iva Pelosini, Francesco Di Mario

  • 1Laboratory of Clinical Pharmacology, Department of Anatomy, Pharmacology and Forensic Sciences, School of Medicine and Dentistry, University of Parma, Parma, Italy. scarpi@tin.it

Digestive Diseases (Basel, Switzerland)
|May 16, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and Use of a Population Pharmacokinetic Model for Characterizing the Pharmacokinetics of Vonoprazan in Pediatric Patients.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Atrophic gastritis of the stomach: a proposal for non-invasive diagnostic algorithm.

Journal of gastrointestinal and liver diseases : JGLD·2026
Same author

The DICA endoscopic score and the CODA clinical score may predict the severity of acute diverticulitis and the risk of hospitalisation: results from an international multicentre prospective cohort study.

Techniques in coloproctology·2026
Same author

Potassium-Competitive Acid Blockers and Hypergastrinemia.

Gastroenterology & hepatology·2026
Same author

Self-Management of Reflux-Like Symptoms: A Patient-Centered Decision-Making Approach.

Digestive diseases (Basel, Switzerland)·2026
Same author

Gastrointestinal Complaints After Fundoplication: Rapid Review and Evidence Mapping.

Current gastroenterology reports·2026
Same journal

Pancreatitis in Familial Dysautonomia Patients.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Treatment outcomes with empirical Clarithromycin-based triple therapy for Helicobacter pylori in Zambia, sub-Saharan Africa.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Endoscopic submucosal dissection-associated bacteremia: proper antibiotic management.

Digestive diseases (Basel, Switzerland)·2026
Same journal

The investigation and treatment of Helicobacter pylori for the prevention of gastric cancer: A narrative review and assessment of management approaches.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Analysis of Helicobacter pylori resistance and its trends in Chongqing: A 10-year retrospective study.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Early-onset colorectal cancer in Australia: environmental, microbial, and policy implications.

Digestive diseases (Basel, Switzerland)·2026
See all related articles

New drugs like potassium-competitive acid blockers (P-CABs) and novel proton pump inhibitors (PPIs) show promise for managing acid-related disorders. Tenatoprazole, a new PPI, offers extended acid suppression, potentially addressing unmet clinical needs in gastroesophageal reflux disease (GERD) and other conditions.

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Drug Development

Background:

  • Pharmacological acid suppression, particularly proton pump inhibitors (PPIs), has revolutionized peptic ulcer and gastroesophageal reflux disease (GERD) management.
  • Despite success, challenges persist in treating refractory GERD, upper gastrointestinal bleeding, NSAID-induced injury, and Helicobacter pylori eradication.

Purpose of the Study:

  • To review current challenges in acid-related disorder management.
  • To explore novel pharmacological agents and formulations under investigation.
  • To highlight promising advancements in acid suppression therapy.

Main Methods:

  • Review of current literature and ongoing clinical trials for new antisecretory drugs.
  • Analysis of the potential of potassium-competitive acid blockers (P-CABs), CCK2-receptor antagonists, and novel proton pump inhibitors (PPIs).

Related Experiment Videos

  • Evaluation of new drug formulations, including immediate-release (IR) PPIs and extended-release compounds.

    • Main Results:

    • Potassium-competitive acid blockers (P-CABs) and CCK2-receptor antagonists are in clinical testing, with P-CABs showing rapid onset but variable efficacy compared to existing PPIs.
    • New PPI formulations, including ilaprazole and tenatoprazole, are under investigation, with tenatoprazole demonstrating a long half-life and extended antisecretory action.
    • Immediate-release (IR) omeprazole improves nocturnal acid control, and similar formulations of other PPIs are anticipated.

    Conclusions:

    • Novel agents like tenatoprazole offer potential advantages over current PPIs for acid suppression therapy.
    • Future developments may include combination therapies and improved formulations to address limitations of existing treatments.
    • Ongoing research promises more effective tools for clinicians managing acid-related disorders.